LENVATINIB is a kinase inhibitor that is indicated for:

Hepatocellular Carcinoma (HCC): as first line therapy in patients with unresectable hepatocellular carcinoma.

Differentiated Thyroid Cancer (DTC): single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.

Renal Cell Cancer (RCC): in combination with Everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.